| Partners
page,page-id-16,page-template-default,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-9.5,wpb-js-composer js-comp-ver-4.12,vc_responsive

Partnering with Vaccibody

Vaccibody is seeking pharmaceutical partners for its lead Product candidate and utilization of the broad Vaccibody Platform Technology both within human and veterinary diseases.

Vaccibody is seeking partners for its first Product candidate, VB10.16, a DNA vaccine delivered by a needle-free jet injector currently tested in a clinical phase I/IIa study to treat HPV16 induced precancerous cervical lesions. See: for more information.


The platform proof of concept has been extensively confirmed by academic and industrial partners and novel product candidates under developement are open for early stage partnering discussions.


Vaccibody has entered an industrial licensing agreement with a veterinary vaccine company for the utilization of the Vaccibody technology in development of poultry vaccines.



For enquiries and further information please contact:
CEO, Martin Bonde





Where to meet us:

JP Morgan, San Francisco, 9-11 Jan

Next Gen Immuno-Oncology, London, 14-15 March

Bio Europe Spring, Barcelona, 20-22 March

NeoAntigen Summit EU, Amsterdam, 24-26 April

Personalized Immunotherapy, Philaldelphia, 2-4 May

Bio International Convention, San Diego, 19-22 June